|
FR3046933B1
(fr)
*
|
2016-01-25 |
2018-03-02 |
Galderma Research & Development |
Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
|
|
US11339136B2
(en)
|
2016-04-18 |
2022-05-24 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
CA3047336A1
(en)
|
2017-01-23 |
2018-07-26 |
Jecure Therapeutics, Inc. |
Chemical compounds as inhibitors of interleukin-1 activity
|
|
US11840543B2
(en)
|
2017-05-24 |
2023-12-12 |
The University Of Queensland |
Compounds and uses
|
|
EP3649112A1
(en)
|
2017-07-07 |
2020-05-13 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
|
|
KR102669722B1
(ko)
|
2017-07-07 |
2024-05-29 |
인플라좀 리미티드 |
신규한 설폰아마이드 카복스아마이드 화합물
|
|
HUE066566T2
(hu)
|
2017-07-24 |
2024-08-28 |
Novartis Ag |
Vegyületek és készítmények NLRP aktivitással összefüggõ állapotok kezelésére
|
|
EP3658538B1
(en)
*
|
2017-07-24 |
2023-04-19 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
TW201910317A
(zh)
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
TW201910316A
(zh)
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
EP3668843A1
(en)
|
2017-08-15 |
2020-06-24 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
EP3707137A1
(en)
|
2017-11-09 |
2020-09-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
PE20210050A1
(es)
*
|
2017-11-09 |
2021-01-08 |
Inflazome Ltd |
Nuevos compuestos de sulfonamida carboxamida
|
|
GB201803394D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166619A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166627A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
EP3759073A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Sulfonamide derivates as nlrp3 inhibitors
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
MA52489A
(fr)
|
2018-05-04 |
2021-03-10 |
Inflazome Ltd |
Nouveaux composés
|
|
US20220267276A1
(en)
*
|
2018-07-03 |
2022-08-25 |
Novartis Ag |
Nlrp modulators
|
|
JP2021529186A
(ja)
*
|
2018-07-03 |
2021-10-28 |
ノバルティス アーゲー |
Ｎｌｒｐ調節剤
|
|
CA3103664A1
(en)
*
|
2018-07-03 |
2020-01-09 |
Novartis Ag |
Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
|
|
CA3104199A1
(en)
|
2018-07-20 |
2020-01-23 |
F. Hoffmann-La Roche Ag |
Sulfonylurea compounds as inhibitors of interleukin-1 activity
|
|
BR112021001044A2
(pt)
|
2018-07-20 |
2021-04-13 |
F. Hoffmann-La Roche Ag |
Compostos de sulfonimidamida como inibidores da atividade de interleucina-1
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
CN112672995A
(zh)
|
2018-08-15 |
2021-04-16 |
英夫拉索姆有限公司 |
新型磺酰胺脲化合物
|
|
CN113056451A
(zh)
*
|
2018-10-24 |
2021-06-29 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
ES2974842T3
(es)
*
|
2018-11-13 |
2024-07-01 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
|
|
PL3880660T3
(pl)
*
|
2018-11-13 |
2025-11-12 |
Novartis Ag |
Związki i kompozycje do leczenia stanów związanych z aktywnością nlrp
|
|
ES2957692T3
(es)
|
2018-11-13 |
2024-01-24 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
|
|
WO2020102574A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Novartis Inflammasome Research, Inc. |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
FI3911631T3
(fi)
|
2019-01-14 |
2025-02-03 |
Zydus Lifesciences Ltd |
Uusia substituoituja sulfonyyliureajohdannaisia
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
CN111848461A
(zh)
*
|
2019-04-29 |
2020-10-30 |
苏州大学 |
Nlrp3炎症小体抑制剂及其制备方法和应用
|
|
WO2020257093A1
(en)
*
|
2019-06-17 |
2020-12-24 |
Olatec Therapeutics Llc |
Method for treating asthma
|
|
EP3986879B1
(en)
|
2019-06-21 |
2024-10-02 |
AC Immune SA |
Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
|
|
WO2021002887A1
(en)
*
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
JP7723652B2
(ja)
*
|
2019-07-17 |
2025-08-14 |
ズーマゲン バイオサイエンシーズ エルティーディー |
多発性硬化症（ＭＳ）の治療のためのＮＬＰＲ３モジュレーターとしてのＮ－（（１，２，３，５，６，７－ヘキサヒドロ－ｓ－インダセン－４－イル）カルバモイル）－４，５，６，７－テトラヒドロベンゾフラン－２－スルホンアミド誘導体および関連化合物
|
|
AU2020314186B2
(en)
|
2019-07-17 |
2026-04-23 |
Zomagen Biosciences Ltd |
NLRP3 modulators
|
|
EP4013761A1
(en)
|
2019-08-16 |
2022-06-22 |
Inflazome Limited |
Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
CN111100042B
(zh)
*
|
2019-11-18 |
2022-05-31 |
苏州诚和医药化学有限公司 |
一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
|
|
CN111018750B
(zh)
*
|
2019-12-19 |
2022-05-27 |
苏州诚和医药化学有限公司 |
一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
|
|
JP7843705B2
(ja)
|
2020-01-22 |
2026-04-10 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
US20230121952A1
(en)
|
2020-02-18 |
2023-04-20 |
Inflazome Limited |
Compounds
|
|
EP4121059A4
(en)
*
|
2020-03-16 |
2023-12-13 |
Zomagen Biosciences Ltd |
NLRP3 MODULATORS
|
|
CN115297855A
(zh)
|
2020-03-19 |
2022-11-04 |
索芙特海尔公司 |
治疗nlrp3相关的疾病的方法
|
|
JP7504234B2
(ja)
*
|
2020-06-11 |
2024-06-21 |
シーセン ファーマシューティカル カンパニー リミテッド |
ジメチルスルホキシミン誘導体
|
|
IL299084A
(en)
|
2020-06-19 |
2023-02-01 |
Ac Immune Sa |
History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
EP4293018A4
(en)
*
|
2021-02-10 |
2025-04-30 |
Hangzhou Innogate Pharma Co., Ltd. |
COMPOUND AS NLRP3 INHIBITOR
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
CN116635374B
(zh)
*
|
2021-05-10 |
2025-05-06 |
康百达（四川）生物医药科技有限公司 |
酰胺衍生物及其应用
|
|
WO2023098612A1
(zh)
*
|
2021-12-03 |
2023-06-08 |
南京明德新药研发有限公司 |
二甲基亚磺酰亚胺衍生物的盐型及晶型
|
|
US20250109126A1
(en)
|
2021-12-22 |
2025-04-03 |
Ac Immune Sa |
Dihydro-oxazol derivative compounds
|
|
EP4554945A1
(en)
|
2022-07-14 |
2025-05-21 |
AC Immune SA |
Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
|
|
CA3261365A1
(en)
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
NEW COMPOUNDS
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
EP4719599A1
(en)
|
2023-06-02 |
2026-04-08 |
Merck Sharp & Dohme LLC |
5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|